Core Insights - MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on precision peptide therapies for endocrine and metabolic disorders [1][3] - The company will participate in two upcoming investor conferences, providing opportunities for engagement with investors [2] Company Overview - MBX Biosciences specializes in the discovery, development, and commercialization of novel precision peptide therapies using its proprietary PEP™ platform [3] - The company is advancing a pipeline that includes canvuparatide (MBX 2109) for chronic hypoparathyroidism, which is preparing for Phase 3 development [3] - The obesity portfolio includes MBX 4291 in Phase 1 development and several discovery and pre-clinical candidates [3] - Imapextide (MBX 1416) is in Phase 2 development for post-bariatric hypoglycemia [3] - The company is based in Carmel, Indiana [3]

Core Insights - MBX Biosciences, Inc. has appointed Laurie Stelzer as an independent director and chairperson of the audit committee, bringing extensive executive and financial leadership experience [1][2] - The company is focused on developing precision peptide therapies for endocrine and metabolic disorders, with a strong pipeline and a catalyst-rich year ahead [2][3] Company Overview - MBX Biosciences specializes in the discovery, development, and commercialization of novel precision peptide therapies using its proprietary PEP™ platform [3] - The company is advancing a pipeline that includes canvuparatide (MBX 2109) for chronic hypoparathyroidism, an obesity portfolio with MBX 4291 in Phase 1, and imapextide (MBX 1416) for post-bariatric hypoglycemia in Phase 2 [3] Leadership and Governance - Laurie Stelzer has over 25 years of experience in finance and leadership roles across various biopharmaceutical companies, including previous positions as CFO at multiple firms [2] - Stelzer's expertise is expected to enhance the company's governance and strategic direction as it progresses through clinical trials [2]

Company Overview - MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel precision peptide therapies for endocrine and metabolic disorders [3] - The company is based in Carmel, Indiana and utilizes its proprietary PEP™ platform for drug discovery [3] Pipeline Development - MBX Biosciences is advancing a pipeline that includes canvuparatide (MBX 2109) for chronic hypoparathyroidism, which is preparing for Phase 3 development [3] - The obesity portfolio includes MBX 4291, currently in Phase 1 development, along with multiple discovery and pre-clinical candidates [3] - Imapextide (MBX 1416) is in Phase 2 development for post-bariatric hypoglycemia [3] Upcoming Events - Kent Hawryluk, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026 [1] - The company presentation is scheduled for January 13, 2026, at 3:45 p.m. PT/6:45 p.m. ET [2] - A live webcast of the presentation will be available on the MBX Biosciences website, with a replay accessible for approximately 90 days [2]

Core Insights - MPM BioImpact has divested its entire stake in MBX Biosciences, selling 1,294,416 shares and reducing its exposure by approximately $14.8 million [2][7] - Despite the divestment by MPM, MBX Biosciences has shown strong performance, with its stock price increasing by 71% over the past year, significantly outperforming the S&P 500 [3][4] Company Overview - MBX Biosciences focuses on developing precision peptide therapies for endocrine and metabolic disorders, with key candidates including MBX 2109, MBX 1416, and MBX 4291 [5] - The company operates as a clinical-stage biopharmaceutical entity, aiming to generate value through research, development, and potential commercialization of its drug candidates [5] - As of the latest market close, MBX's stock price is $33.82, with a market capitalization of $1.5 billion and a net income of -$80.5 million over the trailing twelve months [4] Recent Developments - MBX reported positive topline Phase 2 results for canvuparatide in hypoparathyroidism and completed a $200 million upsized offering, ending the quarter with $391.7 million in cash, sufficient to fund operations into 2029 [9] - The CEO emphasized the potential of canvuparatide in a multibillion-dollar market and highlighted upcoming Phase 3 trials and key milestones expected in 2026 [9] - The stock has rebounded sharply after a significant decline post-IPO, reflecting a changed risk profile due to strengthening clinical data and renewed investor interest [6]

Core Insights - MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders [1][3] - The company will present at the 37th Annual Piper Sandler Healthcare Conference on December 2-4, 2025 [1][2] Company Overview - MBX Biosciences utilizes its proprietary PEP™ platform to discover and develop novel peptide therapies [3] - The company has a pipeline that includes canvuparatide (MBX 2109) for chronic hypoparathyroidism and imapextide (1416) for post-bariatric hypoglycemia, both in Phase 2 development [3] - An obesity portfolio is also in development, including MBX 4291 in Phase 1 and several pre-clinical candidates [3] - The company is based in Carmel, Indiana [3]

Core Insights - MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders [4] Upcoming Investor Conferences - The company will participate in several investor conferences, including: - Guggenheim 2nd Annual Healthcare Innovation Conference on November 10, 2025, in Boston, MA [2] - Stifel Healthcare Conference on November 12, 2025, in New York, NY [2] - Jefferies Global Healthcare Conference on November 19, 2025, in London, UK [2] - TD Cowen Treatment Advancements in Obesity and Related Disorders Summit on November 24, 2025, virtually [3] Company Pipeline - MBX Biosciences is advancing a pipeline that includes: - Canvuparatide (MBX 2109) for chronic hypoparathyroidism, preparing for Phase 3 development [4] - Imapextide (1416) for post-bariatric hypoglycemia, currently in Phase 2 development [4] - An obesity portfolio including MBX 4291 in Phase 1 development and multiple discovery and pre-clinical candidates [4]

Core Insights - MBX Biosciences, Inc. is set to announce topline results from its Phase 2 clinical trial of canvuparatide for chronic hypoparathyroidism on September 22, 2025 [1] - The company will host a conference call and webcast to discuss the trial results, accessible via a live link or by phone [2] - MBX Biosciences focuses on developing precision peptide therapies for endocrine and metabolic disorders using its proprietary PEP™ platform [3] Company Overview - MBX Biosciences is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for endocrine and metabolic disorders [3] - The company is advancing a pipeline of candidates targeting significant unmet medical needs with large market opportunities [3]

Core Insights - MBX Biosciences has initiated a Phase 1 clinical trial for MBX 4291, a novel glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) co-agonist prodrug aimed at treating obesity, marking a significant milestone in addressing global obesity issues [2][6] - The trial is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MBX 4291, with topline results expected in 2027 [2][9] - MBX 4291 is positioned as a best-in-class weight loss prodrug, with potential for once-monthly administration and improved gastrointestinal tolerability compared to existing treatments [2][6] Clinical Trial Details - The Phase 1 trial consists of two parts: Part A involves single ascending doses administered to 5 cohorts of 8 participants each, followed by a 63-day observation period [2][3] - Part B includes multiple ascending doses over 4 weeks, with 3 cohorts of 8 participants each, followed by a 71-day observation period [3][4] - After Parts A and B, the company plans to evaluate multiple ascending doses over 12 weeks in up to two cohorts of 30 participants each, with a total of 12 administrations [4] Product Information - MBX 4291 is developed using the proprietary Precision Endocrine Peptide™ (PEP™) platform, designed to enhance treatment adherence and achieve greater long-term weight loss [6][7] - Preclinical studies indicate that MBX 4291 has a similar activity profile to tirzepatide, an approved weekly GLP-1/GIP co-agonist, but with an extended duration of action supporting once-monthly administration [7] - The company is also advancing other candidates in its pipeline, including canvuparatide for chronic hypoparathyroidism and imapextide for post-bariatric hypoglycemia, indicating a broad focus on endocrine and metabolic disorders [8]

Core Insights - MBX Biosciences has appointed Dr. Andreas Moraitis as Senior Vice President of Clinical Development, bringing extensive experience in endocrinology to lead the clinical development of its lead product candidate, canvuparatide [1][2] Company Overview - MBX Biosciences is a clinical-stage biopharmaceutical company focused on developing novel precision peptide therapies for endocrine and metabolic disorders, utilizing its proprietary PEP™ platform [3] - The company is advancing a pipeline that includes canvuparatide (MBX 2109) in Phase 2 for chronic hypoparathyroidism, imapextide (MBX 1416) in Phase 1 for post-bariatric hypoglycemia, and an obesity portfolio with multiple candidates in development [3] Leadership and Expertise - Dr. Moraitis has over a decade of experience in leading clinical development programs at Corcept Therapeutics, where he oversaw programs for rare endocrine diseases and supported NDA filings [2] - His background includes serving as Clinical Assistant Professor in the Endocrine Oncology Program at the University of Michigan and completing a fellowship in Adult and Reproductive Endocrinology at the National Institutes of Health [2] Product Potential - Canvuparatide is positioned as a meaningful new treatment option for patients with hypoparathyroidism, addressing significant unmet medical needs in this area [2] - The company aims to deliver differentiated endocrine and metabolic compounds to underserved patients, leveraging Dr. Moraitis's expertise to advance its pipeline [2][3]

Core Viewpoint - MBX Biosciences has submitted an Investigational New Drug (IND) application to the FDA for MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug aimed at treating obesity, with a Phase 1 trial expected to start in Q3 2025 [2][3][4] Company Overview - MBX Biosciences is a clinical-stage biopharmaceutical company focused on developing novel precision peptide therapies for endocrine and metabolic disorders [6] - The company is based in Carmel, Indiana, and is advancing a pipeline that includes multiple candidates for obesity and other metabolic disorders [6] Product Details - MBX 4291 is designed as a once-monthly injectable treatment for obesity, potentially offering improved gastrointestinal tolerability and better adherence compared to existing treatments [3][4] - Preclinical studies indicate that MBX 4291 has a similar activity profile and body weight loss effect as tirzepatide, an approved weekly GLP-1/GIP co-agonist, with an extended duration of action [5] Development Pipeline - The company is advancing several early-stage obesity candidates alongside MBX 4291, utilizing its proprietary PEP™ platform to create precision peptides with differentiating characteristics [3][6] - Other candidates in the pipeline include canvuparatide (MBX 2109) in Phase 2 for chronic hypoparathyroidism and imapextide (MBX 1416) in Phase 1 for post-bariatric hypoglycemia [6] Proprietary Technology - MBX's PEP™ platform is designed to enhance peptide drug design, aiming to overcome limitations of traditional peptide therapies by optimizing pharmaceutical properties such as extended action profiles and consistent drug concentrations [7]